Literature DB >> 17652483

Multicenter evaluation of the BD Phoenix Automated Microbiology System for antimicrobial susceptibility testing of Streptococcus species.

Sandra S Richter1, Wanita J Howard, Melvin P Weinstein, David A Bruckner, Janet F Hindler, Michael Saubolle, Gary V Doern.   

Abstract

This multicenter study evaluated the BD Phoenix Automated Microbiology System STREP panel (BD Diagnostic Systems). Antimicrobial susceptibility testing (AST) with 13 agents was performed on 2,013 streptococci (938 Streptococcus pneumoniae isolates; 396 group B streptococci [GBS]; 369 viridans group streptococci [VGS]; 290 beta-hemolytic streptococcus groups A, C, and G; and 20 other streptococci) with the Phoenix system and a broth microdilution reference method. Clinical and challenge isolates were tested against cefepime, cefotaxime (CTX), ceftriaxone (CTR), clindamycin (CLI), erythromycin (ERY), gatifloxacin, levofloxacin, linezolid, meropenem, penicillin (PEN), tetracycline (TET), trimethoprim-sulfamethoxazole, and vancomycin. Clinical isolates with major errors or very major errors (VMEs) were retested in duplicate by both methods. The final results for clinical isolates showed the following trends. For all of the organism-antimicrobial agent combinations tested, categorical agreement (CA) was 92 to 100%, with one exception-VGS-PEN (87% CA; all errors were minor). For S. pneumoniae, there was one major error with CLI (0.1%) and one or two VMEs with CTX (4%), CTR (4.5%), ERY (0.9%), and TET (0.7%). For groups A, C, and G, the CA was 97 to 100% and the only VMEs were resolved by additional reference laboratory testing. For GBS, there was only one VME (TET, 0.3%) and D-zone testing of 23 isolates with CLI major errors (one isolate unavailable) revealed inducible CLI resistance. For VGS, the major error rates were 0 to 3% and VMEs occurred with seven agents (3.5 to 7.1%). The mean times required for organism groups to generate results ranged from 8.4 to 9.4 h. The Phoenix system provided reliable and rapid AST results for most of the organism-antimicrobial agent combinations tested.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17652483      PMCID: PMC2045298          DOI: 10.1128/JCM.00981-07

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  11 in total

1.  Rapid automated antimicrobial susceptibility testing of Streptococcus pneumoniae by use of the bioMerieux VITEK 2.

Authors:  J H Jorgensen; A L Barry; M M Traczewski; D F Sahm; M L McElmeel; S A Crawford
Journal:  J Clin Microbiol       Date:  2000-08       Impact factor: 5.948

2.  Use of the Vitek-1 and Vitek-2 systems for detection of constitutive and inducible macrolide resistance in group B streptococci.

Authors:  Patrick Tang; Peter Ng; Ming Lum; Martin Skulnick; Glen W Small; Donald E Low; Alicia Sarabia; Tony Mazzulli; Katherine Wong; Andrew E Simor; Barbara M Willey
Journal:  J Clin Microbiol       Date:  2004-05       Impact factor: 5.948

3.  Detection of resistance to gatifloxacin and moxifloxacin in Streptococcus pneumoniae with the VITEK 2 instrument.

Authors:  J H Jorgensen; S A Crawford; L M McElmeel; C G Whitney
Journal:  J Clin Microbiol       Date:  2004-12       Impact factor: 5.948

4.  Antimicrobial resistance in viridans group streptococci among patients with and without the diagnosis of cancer in the USA, Canada and Latin America.

Authors:  D J Diekema; M L Beach; M A Pfaller; R N Jones
Journal:  Clin Microbiol Infect       Date:  2001-03       Impact factor: 8.067

5.  Antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis and group A beta-haemolytic streptococci in 2002-2003. Results of the multinational GRASP Surveillance Program.

Authors:  Susan E Beekmann; Kris P Heilmann; Sandra S Richter; Juan García-de-Lomas; Gary V Doern
Journal:  Int J Antimicrob Agents       Date:  2005-02       Impact factor: 5.283

6.  Antibiotic susceptibility profiles for group B streptococci isolated from neonates, 1995-1998.

Authors:  F Y Lin; P H Azimi; L E Weisman; J B Philips; J Regan; P Clark; G G Rhoads; J Clemens; J Troendle; E Pratt; R A Brenner; V Gill
Journal:  Clin Infect Dis       Date:  2000-07-24       Impact factor: 9.079

7.  Antimicrobial resistance among Streptococcus pneumoniae in the United States: have we begun to turn the corner on resistance to certain antimicrobial classes?

Authors:  Gary V Doern; Sandra S Richter; Ashley Miller; Norma Miller; Cassie Rice; Kristopher Heilmann; Susan Beekmann
Journal:  Clin Infect Dis       Date:  2005-06-07       Impact factor: 9.079

8.  Antimicrobial susceptibilities of group B streptococci isolated from patients with invasive disease: 10-year perspective.

Authors:  D R Murdoch; L B Reller
Journal:  Antimicrob Agents Chemother       Date:  2001-12       Impact factor: 5.191

9.  Emergence of high rates of antimicrobial resistance among viridans group streptococci in the United States.

Authors:  G V Doern; M J Ferraro; A B Brueggemann; K L Ruoff
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

10.  Prevention of perinatal group B streptococcal disease. Revised guidelines from CDC.

Authors:  Stephanie Schrag; Rachel Gorwitz; Kristi Fultz-Butts; Anne Schuchat
Journal:  MMWR Recomm Rep       Date:  2002-08-16
View more
  5 in total

1.  Biographical feature: Melvin P. Weinstein, M.D.

Authors:  Betty A Forbes
Journal:  J Clin Microbiol       Date:  2013-06-05       Impact factor: 5.948

2.  Comparison of BD phoenix to vitek 2, microscan MICroSTREP, and Etest for antimicrobial susceptibility testing of Streptococcus pneumoniae.

Authors:  Scott A Mittman; Richard C Huard; Phyllis Della-Latta; Susan Whittier
Journal:  J Clin Microbiol       Date:  2009-09-09       Impact factor: 5.948

3.  Implementing Electric Potential Difference as a New Practical Parameter for Rapid and Specific Measurement of Minimum Inhibitory Concentration of Antibiotics.

Authors:  Nasrin Mobasheri; Mehrdad Karimi; Javad Hamedi
Journal:  Curr Microbiol       Date:  2018-06-05       Impact factor: 2.188

Review 4.  It's not easy being green: the viridans group streptococci, with a focus on pediatric clinical manifestations.

Authors:  Christopher D Doern; Carey-Ann D Burnham
Journal:  J Clin Microbiol       Date:  2010-09-01       Impact factor: 5.948

Review 5.  Antimicrobial Susceptibility Testing: A Comprehensive Review of Currently Used Methods.

Authors:  Ina Gajic; Jovana Kabic; Dusan Kekic; Milos Jovicevic; Marina Milenkovic; Dragana Mitic Culafic; Anika Trudic; Lazar Ranin; Natasa Opavski
Journal:  Antibiotics (Basel)       Date:  2022-03-23
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.